Lysergide d-tartrate

Last updated

Lysergide d-tartrate
Lysergide d-tartrate.svg
Identifiers
  • (6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(2S,3S)-2,3-dihydroxybutanedioic acid
CAS Number
ChemSpider
UNII
Chemical and physical data
Formula C24H31N3O7
Molar mass 473.526 g·mol−1
3D model (JSmol)
  • CN1[C@]2(C(C=3C=4C(C2)=CNC4C=CC3)=C[C@@H](C(N(CC)CC)=O)C1)[H].[C@H]([C@@H](C(O)=O)O)(C(O)=O)O
  • InChI=InChI=1S/C20H25N3O.C4H6O6/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14;5-1(3(7)8)2(6)4(9)10/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t14-,18-;1-,2-/m10/s1
  • Key:HQMPRARIZOUKRO-JDQBHMBOSA-N

Lysergide d-tartrate (MM120) is an investigational new drug that was granted breakthrough therapy status for the treatment of Generalized Anxiety Disorder by the FDA in March 2024. [1] It is a salt of lysergide. [2] [3] The medication is developed by MindMed company.

References

  1. ↑ Meara K (7 March 2024). "FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder". Drug Topics. Drug Topics April 2024. 168. Retrieved 8 March 2024.
  2. ↑ Grinstein JD (14 April 2023). "Licit Activity: MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder". GEN - Genetic Engineering and Biotechnology News. Retrieved 8 March 2024.
  3. ↑ LaMotte S (7 March 2024). "Single dose of LSD provides immediate, lasting anxiety relief, study says". CNN. Retrieved 8 March 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.